FARN

Faron Pharmaceuticals Oy

Health Care First-pass screen £83m

260/1000 Overall fit

AI beneficiary 35% 30

Operating leverage 25% 20

Valuation 25% 30

Downside protection 15% 20

First-pass take

Clinical-stage biotech with zero AI exposure. Phase I/II bexmarilimab and traumakine development carry high execution risk. Document is only an announcement stub; no financial data, cash position, or valuation multiples disclosed.

Flags

clinical-stageno-ai-exposureloss-makingno-valuation-databiotechhigh-risk